Navigation Links
Global Blood Processing Supplies And Equipment Industry
Date:3/14/2013

lyzed with Annual
Sales Figures in US$ Million for Years 2010 through 2018
(includes corresponding Graph/Chart) II-165

Table 83: World Historic Review for Sedimentation Tubes by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America, and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) II-166

Table 84: World 15-Year Perspective for Sedimentation Tubes by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America, and Rest of World Markets for Years 2004, 2011 &
2018 (includes corresponding Graph/Chart) II-167

Table 85: World Recent Past, Current & Future Market Analysis
for Slide Stainers by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) II-168

Table 86: World Historic Review for Slide Stainers by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America, and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) II-169

Table 87: World 15-Year Perspective for Slide Stainers by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia- Pacific (excluding Japan),
Latin America, and Rest of World Markets for Years 2004, 2011 &
2018 (includes corresponding Graph/Chart) II-170

Table 88: World Recent Past, Current & Future Market Analysis
for Specimen Labels by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan)
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related medicine technology :

1. Thoratec Presentation At Barclays Global Healthcare Conference To Be Webcast
2. Perrigo Company To Present At The Barclays Global Healthcare Conference
3. Tucson Symposium attracts over 450 global scientists focused on personalized healthcare
4. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
5. Global Insulin Antidiabetics Market 2012-2016
6. In Vitro Diagnostics Markets Grow at Double the Pace of Pharma Markets in Shift toward Globalization
7. For International Life Sciences, Biotech and Pharmaceutical Events, Top Executives Turn to Global Information
8. HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be Webcast
9. Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
10. Global Gynecological Devices Market is Expected to Reach USD 5.3 Billion by 2018: Transparency Market Research
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014 /PRNewswire/ ... addressing the unmet needs of severely obese patients, ... study of beloranib, a selective inhibitor of methionine ... (PWS), a severe form of genetic obesity.  These ... and body composition, including reductions in body fat ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . ... of less invasive, miniaturized circulatory support technologies that ... today announced that it expects revenues for the ... million, bringing expected full-year 2013 revenues to approximately ... of 87% for 2013 above 2012 reflects the ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, ... for buyers and sellers of high-value chemistry, will hold ... at the Miami Beach Convention ... ) More than 3,500 attendees from ... take part in the conference, which includes on-site education ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... With 30 Installed Inveon Imaging Systems, Siemens ... Position in Preclinical Imaging Centers, HOFFMAN ... adage,says "a picture is worth 1,000 words," ... research where high-resolution images can validate years ...
... Results Seen Since Presentation ... to Include Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, ... data from a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 ...
Cached Medicine Technology:Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 2Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 3Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 4Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 5Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
(Date:4/14/2014)... Ohio A new study identifies a molecule that ... suggests that the molecule could be an important target ... tumor progression. , The study of microRNA-135b (miR-135b) in ... the journal Cancer Cell and was led ... Center Arthur G. James Cancer Hospital and Richard ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... WASHINGTON, April 14In dense, urban centers around the world, ... streets surrounded by tall buildings that block sunlight. And ... are jammed closer together, the darkness will only spread. ... developed a corrugated, translucent panel that redirects sunlight onto ... rooftops and hung over the edge at an angle, ...
(Date:4/14/2014)... aren,t breastfed or not breastfed for long are ... related health problems later in life, according to ... to hypothesize that breastfeeding was important to influencing ... (Northwestern University), a CIFAR (Canadian Institute for Advanced ... program. "It changes the microbiome. It promotes development ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Low birth weight, less breastfeeding create later health risks 2
... how hypertension is treated, experts say , SUNDAY, March ... large five-year study points to fluctuations in blood pressure ... , In the study, British researchers tracked the health ... or calcium channel blocker medication to curb high blood ...
... traditional screening tests for potential anti-cancer drugs, scientists ... technique that more closely simulates the real-world conditions ... normal cells. Because these neighboring cells key ... microenvironment" can alter the effectiveness of anti-cancer ...
... fewer side effects than the conventional medication used during a ... a Henry Ford Hospital study. Researchers say the 25 ... such as abnormally low blood pressure or slow heart beat ... Additionally, patients showed no signs of heart block, a condition ...
... exam, study finds , SUNDAY, March 14 (HealthDay News) -- ... and collegiate hockey players in a U.S. study had abnormal ... see if abnormal MRI results are found incidentally in active ... the department of family medicine and orthopedics at Hershey Medical ...
... no effect in shielding users from cardiovascular woes, study ... that two available drugs could help prevent diabetes and ... sugar metabolism have been dashed by a major international ... other reasons -- Diovan (valsartan), a blood pressure medication; ...
... pressure to normal levels below currently recommended levels ... fatal or nonfatal cardiovascular disease events in adults with ... for cardiovascular disease events, according to new results from ... (ACCORD) clinical trial. Similarly, treating multiple blood lipids with ...
Cached Medicine News:Health News:More Evidence That Swings in Blood Pressure Raise Stroke Risk 2Health News:New cancer drug screening technique more closely mirrors reality 2Health News:New cancer drug screening technique more closely mirrors reality 3Health News:Scans May Be Misleading for Hockey Players 2Health News:2 Drugs Fail to Prevent Diabetes in the Overweight 2Health News:2 Drugs Fail to Prevent Diabetes in the Overweight 3Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 3Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 4Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 5Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: